Winner
Sandoz, Redefining Medical Affairs Excellence in Biosimilar Launches
by Syneos Health Communications on behalf of Sandoz
Summary of work
Sandoz has set a new benchmark for peer-to-peer scientific exchange, delivering a Medical Affairs-led programme that redefines stakeholder engagement in neurology. Entering a biosimilar-naïve multiple sclerosis (MS) market, Sandoz identified a critical need to educate and address misconceptions among neurologists, nurses, pharmacists, and patient organisations.
Through a multistakeholder advisory approach, the programme established a peer-led content generation model that seamlessly combined high-impact digital education, in-person engagement, and an adaptive publication plan; all designed to close knowledge gaps and build confidence in biosimilars.
This initiative stands out for its robust three-pillar strategy, integrating: • Live scientific exchange to foster discussion and advocacy • Needs-driven, evidence-based publications to provide clinical clarity • Digital medical education tailored to diverse learning preferences
The results? A measurable increase in neurologist confidence, over 23,000 HCPs engaged globally via digital education, and publications exceeding 22,000 views in 2023–24, far surpassing all targets.
By combining scientific credibility, stakeholder-led co-creation and digital education, Sandoz has demonstrated how Medical Affairs can drive scientific exchange with excellence, setting the stage for wider biosimilar adoption. This initiative exemplifies how responsible, pre-commercialisation engagement can enhance trust, shift perceptions, and shape the future of patient care.
Judges’ comments
‘Sandoz, redefining medical affairs excellence in biosimilar launches’ was a stand-out entry and clear winner in this category. The programme was comprehensive, expert-driven and targeted a key area of HCP medical education. The team really understood the challenges it needed to overcome and delved into specific audience needs. The metrics were impressive, with the significant increase in neurologists’ confidence in prescribing biosimilars demonstrating a meaningful behavioural shift.
